

## Welcome! Guide to Maximizing Your Medical Affairs Social Media Presence



The views expressed in this Webinar are those of the presenters, and are not an official position statement by MAPS, nor do they necessarily represent the views of the MAPS organization or its members.

This presentation is for informational purposes only and is not intended as legal or regulatory advice.

### **Presenters**



### Scott Houck

Therapeutic Unit Scientific Lead MedThink SciCom



Leslie Rotz

Director, Digital Strategy & Operations MedThink SciCom



#### Jenny Ghith

Innovation Lead, Global Scientific Communications Pfizer Oncology

Content for this presentation reflects the collective experience and opinions of the presenter. It is not intended to represent the past or current views of Pfizer.

## **Educational Objectives**

This session will provide a learning opportunity for our audience by:



Providing best practices for social media engagement



Giving insight into the process for building a social media strategy and project plan



Helping identify any compliance or practical challenges associated with social media

This discussion aims to go beyond creating a social media presence and focus on maximizing the impact of social media

## Use of Social Media by Medical Audiences

# Do you feel Medical Affairs should be playing a leading role in social media initiatives?

- a. Definitely
- **b.** Probably
- c. Probably not
- **d.** Definitely not

## Social Media Is Ubiquitous and Growing

**1.** Statista. https://www.statista.com/statistics/617136/digital-population-worldwide. Accessed October 6, 2021.

2. eMarketer. https://www.emarketer.com/content/us-social-trends-for-2020. Accessed October 6, 2021.

 LinkedIn. https://business.linkedin.com/marketingsolutions/healthcare/measuring-healthcare-marketings-worth. Accessed October 6, 2021.

4. eMarketer. https://www.emarketer.com/content/us-healthcare-pharmadigital-ad-spending-2020. Accessed October 6, 2021.




Worldwide, >4.6 billion people use social media<sup>1</sup>

In 2020, US social media advertising spend reached \$43 billion, a 20% increase from 2019<sup>2</sup>

Over **45% of HCPs** are on LinkedIn<sup>3</sup>

In 2020, spending on digital advertising in the healthcare industry will grow by 14% to reach \$9.5 billion<sup>4</sup>

Social Media Use in Oncology Is Increasing and Can Help Increase Visibility of Data **2020 survey of oncologists' use of social media** (N=101)<sup>a</sup>



2019 study of 189 articles in the journal Academic Medicine<sup>1</sup>

63% Increase in page views after 30 days of tweeting about an article

<sup>a</sup>Global oncologists from the United States and EU5 countries were recruited to participate via the SERMO research panel in June 2020 **1.** Maggio et al. *PLoS One.* 2019;14:e0223992.


# Making the Case for a Medical-Led Initiative

## Data Dissemination Is a Pillar of Medical Affairs

Overarching goal: expand engagement of the healthcare community and address knowledge gaps as part of scientific exchange



### Evolution of Working Model and Subject Matter Expertise Are Needed to Enable Data Dissemination



### Why Engage on Social Media as Medical?

### **Open social media platforms can**



Help to increase community awareness of key scientific data



Transform approaches towards omnichannel communication



Help audiences focus on what is meaningful in a sea of information overload

There are a numerous social media platforms with different audiences and qualities. Currently, there is a primary focus on Twitter, but the world is evolving

As with any new technology, there are limitations and issues that need to be overcome, such as compliance issues, misinformation, and popularity bias

How many times per week do you use social media (e.g., Twitter, LinkedIn) for professional purposes?

- a. >11 times per week
- **b.** 4-10 times per week
- c. 1-3 times per week
- d. Never

### Survey Provides First Data Into Preferences of Oncologists Seeking Medical Content on Social Media

#### Oncologists who are active social media users FOLLOW ACCOUNTS MOST RELEVANT TO THEM

## 69%

Are more likely to follow an ONC-specific account than a non-specific one

54%


Would unfollow a pharmaceutical company handle that posts too much information unrelated to oncology



US Oncologists are ~20% more likely to unfollow a company handle that posts too much content unrelated to oncology than their EU5 counterparts

## SPONSORED CONTENT IS EFFECTIVE AT INTRODUCING RELEVANT CONTENT.

US oncologists are more likely to notice news feed ads than EU5 oncologists



Results of a SERMO survey of 100 oncologists who actively use social media professionally (60 from the US, 40 from the EU5) in August 2021.

Some Companies May Utilize Medical Affairs-Driven Social Media Profiles

Based on accounts identified through a manual audit of social media.



Of the 12 top pharmaceutical companies reviewed...

**100%** had corporate social media profiles

83% had profiles for recruiting and employee retention

**66%** use social media for product promotion

**58%** had profiles that shared medical content, possibly managed by Medical Affairs teams

## Social Media Can Be Used to Disseminate a Variety of Types of Information

|                         |                                                      |                                                | 1                                                                                                                                                                                                                                        |
|-------------------------|------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| analysis of Korean pati | ents receiving #mBC                                  |                                                |                                                                                                                                                                                                                                          |
|                         |                                                      |                                                |                                                                                                                                                                                                                                          |
| 0 0                     |                                                      |                                                |                                                                                                                                                                                                                                          |
|                         | 65                                                   |                                                |                                                                                                                                                                                                                                          |
|                         | 1 Ann                                                |                                                |                                                                                                                                                                                                                                          |
| 01                      | 1                                                    |                                                |                                                                                                                                                                                                                                          |
|                         | s important at Pfizer. Se<br>analysis of Korean pati | s important at Pfizer. See efficacy and safety | g outcomes of #breastcancer therapy in different subgroups of<br>s important at Prizer. See efficacy and safety results from a<br>analysis of Korean patients receiving #mBC therapy, published in<br>al of Breast Cancer bit.ly/3kjezxo |

|                 |            | _ |       |
|-----------------|------------|---|-------|
| LVEF ≤40%       |            |   | 75.5% |
| LVEF ≥50%       |            |   | 10.2% |
| LVEF >60%       |            |   | 6.1%  |
| It is not defin | ned by EF. |   | 8.2%  |


#### Highlight journal articles and conference materials

| https://doi.org/10.4048/jbc.2021.24.e13<br>pISSN 1738-6756-eISSN 2092-9900 |                                                    | Journal of<br>Breast Cancer    |
|----------------------------------------------------------------------------|----------------------------------------------------|--------------------------------|
| Brief Communication                                                        | Palbociclib Plus Fulvest<br>Patients from PALOMA-3 |                                |
|                                                                            | Receptor-Positive/Huma                             | an Epidermal                   |
|                                                                            | <b>Growth Factor Receptor</b>                      | 2-Negative                     |
|                                                                            | <b>Advanced Breast Cance</b>                       | r                              |
| G OPEN ACCESS                                                              | Xin Huang States of NAT                            | Overview of identified studies |
|                                                                            | Division of Hemai                                  |                                |

#### Interactive polling

| sed on current @ACCinTouch and @American_Hea<br>e definition of HFrEF? 3/13 | irt guidelines, what is |
|-----------------------------------------------------------------------------|-------------------------|
| .VEF ≤40%                                                                   | 75.5%                   |
| VEF ≥50%                                                                    | 10.2%                   |
| VEF >60%                                                                    | 6.1%                    |
| t is not defined by EF.                                                     | 8.2%                    |
| votes - Final results                                                       |                         |

#### Link to Medical Information




#### Link to key educational sites



## Medical-Led Twitter Handles Are Followed and People Interact With the Content





<sup>a</sup>Data as of October 6, 2021. <sup>a</sup>For ePubs, includes articles published online in the same journal within about 1 week of the highlighted article. <sup>b</sup>For articles with available article-level page view metrics.

**1.** Chari et al. Presented at 17th Annual Meeting of ISMPP. 2021.

Social media will continue to be a major source of information for the healthcare community

Its important for Medical Affairs to understand social media and consider utilizing it



Data dissemination is a key pillar of Medical Affairs and is evolving to include new channels

Social media is increasingly being used by HCPs to help inform their clinical decisionmaking

Use of medical-led social media accounts can lead to increased views of and engagement with key data

Limitations of social media include:

- Misinformation online
- Lack of desire to follow corporate accounts
- Need for clarity on roles and responsibilities for Medical Affairs versus other functions

## How Do You Create a Medical Affairs Social Media Strategy?



Determines how your competitors use social media and how your audience interacts with content



Defines campaign framework, editorial calendar planning, standard responses, and funnel for content creation and approval



Packages FDA guidelines with proposed SOPs and example content to gain MLR alignment



Aligns measurable data with key objectives and plans for future expansion

Take time to gain internal alignment and solidify processes before launch

## Landscape Analysis

Landscape Mapping Identifies Areas of Opportunity



Crystalize objectives

Define critical information to scope

Conduct targeted research for full external review

Identify opportunities and challenges

Draft SWOT analysis

### Leveraging Social Listening for Landscape Analysis



Determines the overall perceptions and topics of discussion around specific events (eg, key conference presentation)



Identifies key topics of discussion over a given time window and how perceptions are changing over time



Identifies what known OLs are saying on social media in general or on a certain topic




Determines who is driving the conversation around a drug or therapeutic area on social media

Always assess channel relevance for a specific audience before conducting any social listening analyses

DOL, digital OL; OL, opinion leader.

## **Target Audience Profiling**

### **Develop Personas for Key Audiences**



## Gain Insights Directly From DOLs on Dissemination Through Social Media

### **Objective**

To gain insight from DOLs on best practices for disseminating information via open social media channels (e.g., medical Twitter handle)

#### **Potential solution**

Facilitate an advisory board with ~10 to 20 DOLs to gain insight on best practices for disseminating information via open social media and guidance on the best places to engage DOLs in other settings



## **Concept Creation**

## Global Social Media Campaign Begins With Overarching Narrative



Consistent, deliberate messaging builds your brand

Purposefully drive the conversation

Focus your engagement to have a **bigger impact** and save resources

Remain relevant to your customers

Build trust and reputation

## Global Narrative Sets Foundation for Engagement Plans



### **Initial Strategy and Guiding Principles**

### Strategic framework working session

Identify opportunity



Define goal and measurable objectives



Define audiences and provide each with key messages



Align voice/tone and style guide with other channels

### **Project Plan and Process**



Campaign framework and profile creation

- Define the opportunity and audience
- Set campaign goals and objectives
- Define resourcing and support
  - Internal partners and roles
  - Agency partners and roles
- Initial setup of profile
  - Creative (images) and bio
  - SOP for responses
  - Community guidelines
  - Develop FAQs catalog with draft responses



## Engagement plan and editorial calendar

- Create a quarter-byquarter timeline of
  - Engagement
    opportunities (events)
  - Content opportunities (themes)
- Collaborate with corporate affairs for resourcing purposes
- Share with MLR for conceptual review

## Content creation and approval process

- Create content monthly or quarterly
  - Copy, images, multimedia
- Define intake process for content
- Submit for MLR approval

## Deployment and measurement

- Coordinate final content handoff and scheduling requests
- Coordinate future live sharing opportunities
  - Discuss conference live sharing plan with MLR propose conference playbook to include preapproved tweets and images/videos
- Align metrics dashboard with initial objectives

## **Content Creation and Curation**

## Engagement Plans Feed Into Editorial Calendar




#### **Compile quarterly editorial calendar**

- Define format, preferably flexible/editable and accessible
- Inputs from across various therapeutic areas
- Publications, conferences, "days," etc

#### **Content planning**

Define a cadence for number of posts per month, submitted for medical review in quarterly batches

Content and creative assets can include a variety of formats Custom/Stock images, animated GIFs, short video clips, infographics, visual abstracts, polls





**Content opportunity** 

Relevant stakeholders—supporters or detractors?


**Relevant events** 

Timeline

**KPIs and relevant metrics** 

## **Content Optimization**

### **Approaches to Enhance Audience Reach**



## Driving Awareness









## **Content Consumption**



## Community/Channel Management


## **Review Process Considerations**

Familiarize team with FDA guidelines and relevant social media policy considerations

| പര്പ           |
|----------------|
| $\checkmark$ — |
| × –            |
| × —            |

Define review guidance for individual posts

- Agree on appropriate cadence for reviews
- SOP for any ad hoc requests
- Test and refine deployment times across platforms



Develop SOP for publishing content

 Test and refine deployment times across platforms



Develop clear response strategy

- Monitor content
- Identify which types of content will/will not necessitate responses
- Draft a catalog of presumed frequent questions and comments
  - Draft preplanned responses
  - Customer care and medical information plan to include sources for users to contact with questions or concerns

## **Analytics and Reporting**

### Metrics and Analytics Continually Guide Optimization of Social Media Campaign

### **KEY OBJECTIVES**

Elevating visibility of important medical content

Providing content in a manner aligned with values and how audiences want to receive the information

Engaging in meaningful scientific dialogue

### **PRIMARY KPIs**

Dialogue rate (replies/post)

Amplification rate (shares/post)

Appreciation rate (likes/post)



ONGOING Tactical performance



QUARTERLY Campaign performance



ANNUAL Performance against annual goals Medical Affairs Professional Society (MAPS) | 2021

## **Takeaway Messages for Success**




Research your audience to identify the optimal platforms to use Know what your competitors are doing

 Monitor conversations that are relevant to your industry




Establish a voice and tone



Choose the right time and amount to post

Do not repost the same content across various platforms



Measure often and optimize just as often

# Thank you!

# Questions?